View clinical trials related to Glioma.
Filter by:Research purposes: 1. To obtain the metabolic characteristics of glioma molecular imaging through a multimodal image recognition system. 2. To determine whether molecular imaging metabolic parameters can characterize the molecular typing of glioma by analyzing the relationship between metabolic parameters and tumor subtypes 3. To get metabolic classification based on metabolic parameters of glioma molecular imaging, and to identify the relationship between metabolic subtypes and surgical resection, radiotherapy and chemotherapy, and prognosis and further refine the molecular classification of glioma. Research Background: Glioma is the most common primary intracranial malignant tumor, accounting for 80% of central nervous system malignant tumors. It is highly invasive, with a surgical recurrence rate of up to 90%. The prognosis is extremely poor, which has caused a great burden. There are different molecular subtypes of glioma with distinct molecular biological characteristics, resulting in various prognosis of patients. With the continuous development of basic and clinical research of glioma and the advent of various new drugs and treatment technologies, molecular pathological diagnosis based on the individual level of glioma patients is particularly important. Clarifying the molecular pathology type before surgery will help the clinical diagnosis and prognostic judgment of glioma, and is of great significance for the optimization of treatment options. Based on the establishment of glioma molecular typing system, the project team use noninvasive molecular imaging technology to clarify the characteristics of molecular subsets of glioma based on the tumor metabolic parameters. Through combining deep learning-based target detection and image recognition with big data analysis, it has great potential in the clinical research of glioma diagnosis, prognosis and treatment options, which could provide a scientific basis for the establishment and promotion of glioma molecular analysis and recognition system.
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection. In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor. If positive PK results are demonstrated in ≥50% of Phase 0 participants and at least 5 participants are enrolled into Phase 2, up to approximately 40 additional participants will be enrolled in the dose expansion cohort in order to achieve a total of 25 participants enrolled into Phase 2 (lead-in cohort + dose expansion).
This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-naïve patients after resection of glioblastoma.
This trial uses magnetic resonance elastography (MRE) to estimate tissue stiffness (hardness or softness of the tissue) in tissue that is affected by radiation treatment (radiation necrosis) and tumor tissue that has come back (recurrent) after treatment in patients with gliomas. Diagnostic procedures, such as MRE, may estimate the differences in tissue stiffness between radiation necrosis and recurrent glioma post treatment and ultimately lead to a more accurate diagnosis and/or surgery, and/or a better assessment of the disease's response to treatment.
Retrospective longitudinal follow-up in patients with diffuse low-grade glioma with multimodal MRI assessment
This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The names of the study drugs involved in this study are: - Marizomib - Panobinostat
This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations. Subjects will be seen on an every six week basis for 1 year or longer. Subjects who continue to receive Toca FC will receive the dose described in the "parent" protocol. If the Toca FC dose is adjusted for any reason, the serum concentration will be monitored. Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) scans will be performed as per standard of care. If the subject has recurred/progressed, repeat intracranial injection of Toca 511 followed by Toca FC treatment may be offered to consenting patients. Subjects who enter the study to continue Toca FC and subsequently discontinue Toca FC, and subjects who are only willing or able to perform limited testing will have viral testing alone, at the appropriate intervals. After the first year, subjects will be seen twice yearly for the next 4 years and then contacted yearly for the next 10 years. All subjects will be followed on study for at least 5 years regardless of whether they are taking Toca FC.
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.